Phase II Trial of Neoadjuvant Cisplatin, 5-Fluorouracil and Interferon-Alpha in Operable Squamous Cell Carcinoma of the Esophagus

Publisher： Karger

E-ISSN： 1421-9794|54|4|315-322

ISSN： 0009-3157

Source： Chemotherapy, Vol.54, Iss.4, 2008-08, pp. : 315-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Trial of Combination Cisplatin, 5-Fluorouracil and Interferon-α in the Treatment of Advanced Esophageal Carcinoma

By  

Chemotherapy, Vol. 48, Iss. 4, 2002-09 ,pp. : 211-216

Karger

Access to resources Recommend Favorite

Effects of Cisplatin, 5-Fluorouracil, and Radiation on Cell Cycle Regulation and Apoptosis in the Hypopharyngeal Carcinoma Cell Line

By  

Chemotherapy, Vol. 51, Iss. 2-3, 2005-06 ,pp. : 103-110

Karger

Access to resources Recommend Favorite

Correlations between Thymidylate Synthase Expression and Chemosensitivity to 5-Fluorouracil, Cell Proliferation and Clinical Outcome in Head and Neck Squamous Cell Carcinoma

By  

Chemotherapy, Vol. 55, Iss. 1, 2008-11 ,pp. : 36-41

Karger

Access to resources Recommend Favorite

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin

By  

Chemotherapy, Vol. 56, Iss. 4, 2010-08 ,pp. : 268-274

Karger

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite